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Summary
Background Stress is commonly cited as a risk factor for psoriasis and atopic
eczema, but such evidence is limited.
Objectives To investigate the association between partner bereavement (an extreme
life stressor) and psoriasis or atopic eczema.
Methods We conducted cohort studies using data from the U.K. Clinical Practice
Research Datalink (1997–2017) and Danish nationwide registries (1997–2016).
The exposed cohort was partners who experienced partner bereavement. The
comparison cohort was up to 10 nonbereaved partners, matched to each
bereaved partner by age, sex, county of residence (Denmark) and general practice
(U.K.). Outcomes were the first recorded diagnosis of psoriasis or atopic eczema.
We estimated hazard ratios (HRs) and confidence intervals (CIs) using a stratified
Cox proportional hazards model in both settings, which were then pooled in a
meta-analysis.
Results The pooled adjusted HR for the association between bereavement and pso-
riasis was 101 (95% CI 098–104) across the entire follow-up. Similar results
were found in other shorter follow-up periods. Pooled adjusted HRs for the asso-
ciation between bereavement and atopic eczema were 097 (95% CI 084–112)
across the entire follow-up, 109 (95% CI 086–138) within 0–30 days, 118
(95% CI 104–135) within 0–90 days, 114 (95% CI 106–122) within 0–365
days and 107 (95% CI 102–112) within 0–1095 days.
Conclusions We found a modest increase in the risk of atopic eczema within 3
years following bereavement, which peaked in the first 3 months. Acute stress
may play a role in triggering onset of new atopic eczema or relapse of atopic
eczema previously in remission. We observed no evidence for increased long-
term risk of psoriasis and atopic eczema following bereavement.
What’s already known about this topic?
• Psychological stress is commonly cited as a risk factor for psoriasis and atopic
eczema. However, clinical evidence supporting such associations is limited.
• Current epidemiological evidence for the relationship is limited by small sample
sizes and difficulty measuring stress.
© 2019 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd
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What does this study add?
• In two population-based cohort studies, there was no evidence of an increased risk
of psoriasis associated with partner bereavement.
• There was a short-term increased risk of atopic eczema in the 3 years following
partner bereavement, which peaked during the first year. However, there was no
evidence of an increased long-term risk of atopic eczema.
• Acute stress may trigger onset or relapse of atopic eczema, leading to an increased
risk of atopic eczema in the short term following partner bereavement.
Psoriasis and atopic eczema are inflammatory skin disorders
associated with substantial morbidity, representing major
health burdens.1 The prevalence of psoriasis ranges from 12%
to 85% in Europe2 and from 2% to 3% in the U.K.3 and
Denmark.4 Atopic eczema affects at least 15% of children and
7% of adults globally.5,6 In addition, psoriasis and atopic
eczema have a range of health consequences, including
depression,7,8 cardiovascular diseases9,10 and increased mortal-
ity,11,12 leading to substantial health expenditure.13–15 Thus,
understanding the aetiology of psoriasis and atopic eczema is
a major priority.
Psychological stress is commonly cited as an important fac-
tor associated with psoriasis and atopic eczema. It has been
postulated that stress activates the hypothalamic–pituitary–
adrenal axis, resulting in increased levels of T helper and natu-
ral killer cells. Importantly, T cells are involved in the patho-
genesis of psoriasis and atopic eczema.16–19 However, clinical
evidence supporting associations between stress and these con-
ditions is limited.20
A recent systematic review investigating the association
between stress and psoriasis found that existing studies were
limited by small sample size, difficulty in measuring stress,
and misclassification of negative life events due to recall
bias.21 Addressing these limitations requires population-based
epidemiological studies with precise timing of negative life
events.
According to the Social Readjustment Rating Scale, partner
bereavement is perceived as one of the most stressful acute life
events.22 It impacts most people negatively irrespectively of
coping mechanisms.23,24 Therefore, partner bereavement is
often used to elucidate the role of extreme stressors in impor-
tant health outcomes, including cardiovascular disease,25,26
infection27,28 and death.29,30
Given uncertainty about the role of stress as a trigger of dis-
ease onset, we investigated whether partner bereavement was
associated with new onset of psoriasis and atopic eczema in
two population-based matched-cohort studies. We examined
whether the associations differed by (i) time since bereave-
ment and (ii) whether the death of a partner was expected.
Patients and methods
Setting
In the U.K. we used primary care data from the Clinical Prac-
tice Research Datalink (CPRD)31 and linked death data from
the Office for National Statistics (ONS), hospital admissions
data from Hospital Episode Statistics and deprivation data from
the Index of Multiple Deprivation.
In Denmark we used nationwide registries linked using the
unique personal identifier assigned to all Danish residents. We
defined the study population and obtained demographic infor-
mation, including civil and vital status, from the Danish Civil
Registration System.32 Other registries provided data on hospi-
tal contacts including inpatients, outpatient hospital clinics and
emergency records (Danish National Patient Registry),33 dis-
pensed prescriptions (Danish National Prescription Registry)34
and education (Population Education Registry).35
We aimed for the U.K. and Danish studies to be as similar
as possible to ensure comparability (Appendix S1; see Sup-
porting Information). We used data from 1 January 1997 to
31 July 2017 in the U.K. and from 1 January 1997 to 31
December 2016 in Denmark.
Couple identification
In the U.K., we identified partners eligible for inclusion using a
previously developed algorithm.26,27,29,30 Individuals were eli-
gible for inclusion from the latest of either the date of the prac-
tice meeting CPRD quality control standards or the study start
date. We identified eligible opposite-sex couples in the same
household, with an age gap of ≤ 10 years and with no younger
adults in the same household aged within 15 years of either of
the couple. We excluded couples where both partners were <
© 2019 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd
on behalf of British Association of Dermatologists.
British Journal of Dermatology (2019)
2 Partner bereavement and psoriasis and atopic eczema, A.Y.S. Wong et al.
40 years old or ≥ 95 years old; either partner had a code indicat-
ing residence in a communal establishment; and couples who
belonged to households with > 10 registered members.
In Denmark we identified partners using an algorithm
developed by Statistics Denmark, which registers the unique
personal identifiers of a person’s spouse or partner by com-
bining data on civil status, demographics, address and close
kinship (e.g. parents, siblings and children). Because more
detailed data were available in Denmark, we allowed an age
difference of up to 15 years between partners.27
Matched study population
Among eligible couples, we identified the partner who died
first and included the surviving partner in the bereaved cohort.
We considered the date of the partner’s death as the index
date for the bereaved partner. In the U.K., we used dates of
death from the ONS when available (598%) and from CPRD
for those without ONS linkage (402%).
For each bereaved person, we then identified a matched com-
parison cohort by sampling (with replacement) up to 10 part-
ners on age, sex (both settings), county of residence (Denmark)
and general practice membership (U.K.) on the index date. We
did not include individuals in the comparison cohort who had
experienced the death of a partner prior to the index date. We
excluded couples who both died on the index date as they did
not contribute person time. We required all individuals to have
≥ 1 year of registration history prior to the index date in the
U.K., to allow adequate time for recording of covariates and his-
tory of psoriasis and atopic eczema.
Outcomes
We considered the first-ever recorded diagnosis of psoriasis or
atopic eczema after bereavement to represent recent onset of
psoriasis or atopic eczema, based on relevant morbidity codes
(Read codes and International Classification of Diseases, 8th
and 10th Revision codes) and validated diagnostic algorithms
(Appendix S2 for the U.K. and Appendix S3 for Denmark; see
Supporting Information).36–38 Code lists for the U.K. are avail-
able online (https://datacompass.lshtm.ac.uk/1262). We
excluded individuals with any diagnosis of the relevant out-
come prior to the index date. We followed cohorts from the
index date until the earliest of: diagnosis of a specific out-
come, last data collection date from practice (U.K.), transfer
out of the practice of either of the couple (U.K.), emigration
of either of the couple (Denmark), death or the study end
date. If a person in the comparison cohort experienced
bereavement, he or she was censored 1 day before bereave-
ment and was subsequently included in the bereaved cohort
(Fig. S1; see Supporting Information).
Covariates
For members of the bereaved and comparison cohorts, we
identified comorbidities, deprivation and lifestyle covariates.
We defined comorbidity burden on the index date using the
Charlson Comorbidity Index (CCI),39 which we categorized
into low (0 points), intermediate (1–2 points) and high (≥
3 points). In the U.K. we used the quintiles of Index of
Multiple Deprivation as a measure of socioeconomic depriva-
tion, while in Denmark we used educational-level data as a
proxy for socioeconomic status, categorized as short (7–10
years), medium (11–12 years) or long (≥ 13 years). In the
U.K. we included lifestyle data on body mass index (accord-
ing to World Health Organization guidelines), alcohol con-
sumption (current, ex-drinker, nondrinker) and smoking
(current, ex-smoker, nonsmoker) (Appendix S2; see Support-
ing Information).
We also determined whether bereavement was expected or
unforeseen (risk of partners’ deaths) using an age-adjusted
CCI score for the partner who died based on comorbidity
recorded up to 1 month before their death (Appendix S2). As
an alternative measure, we identified records for terminal dis-
ease before the date of death (Appendix S2).
Statistical analysis
We used Cox regression to compute hazard ratios (HRs) with
95% confidence intervals (CIs), stratified by matched sets for
all models. We first fitted an ‘unadjusted stratified model’,
implicitly adjusted for age and sex and general practice (U.K.)
and also county of residence (Denmark). In sequential models,
we adjusted for study participants’ CCI in the ‘adjusted model’
and then additionally adjusted for deprivation status (U.K.),
educational level (Denmark) and lifestyle variables (U.K.) in
the ‘fully adjusted model’. Due to incomplete lifestyle data
(U.K.), we investigated patterns of missing data using condi-
tional logistic regression. As lifestyle data are highly unlikely
to be missing at random and we lacked data on probable pre-
dictors of missingness, we concluded that imputation tech-
niques would not be appropriate to correct potential biases.
We therefore used a simpler complete-case approach.40
As we hypothesized that the effect of bereavement would
be highest in the short term following a partner’s death,26 we
examined the association by time since the index date (0–30,
0–90, 0–365 and 0–1095 days). We first separately conducted
the analyses for the U.K. and Denmark, and then pooled the
results (from adjusted models) in a random-effects meta-ana-
lysis, using the DerSimonian and Laird method to pool vari-
ances.41 We assessed the assumption of proportional hazards
for the overall study period, and for each specific time period,
by visual inspection of log–log plots. Because of evidence of
nonproportionality (Fig. S2; see Supporting Information), we
further evaluated whether the HRs changed over time by strat-
ifying follow-up since bereavement into several periods (0–
30, 31–90, 91–365, 366–1095 and > 1095 days) and per-
formed likelihood ratio tests to analyse effect modification.
In each setting, we estimated HRs in subgroups defined by
age, sex and risk of partners’ deaths (by terminal disease and
age-adjusted CCI of the partner who died) and performed
likelihood ratio tests to explore possible effect modification by
© 2019 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd
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these characteristics. We performed several sensitivity analyses
to explore the robustness of our results (Table S1; see Sup-
porting Information). We specified all analyses a priori unless
otherwise stated. Study reporting is consistent with the
RECORD statement (Table S2; see Supporting Information).42
We performed analyses using Stata/MP 151 (StataCorp, Col-
lege Station, TX, U.K.) and SAS 94 (SAS Institute Inc., Cary,
NC, U.S.A.).
Results
Patient characteristics
Figure 1 presents a flowchart for inclusion in the study. The
median age was 74 years in the U.K. and 71 years in Den-
mark, and approximately 66% of individuals were women in
both settings (Tables 1 and 2). More individuals under 50
years were included in Denmark in both the psoriasis and ato-
pic eczema analyses. In both analyses, bereaved individuals
were more likely than nonbereaved individuals to have a
higher CCI score and more deprivation (U.K.) (Table 1) and a
lower educational level (Denmark) (Table 2).
Psoriasis
The pooled HR (adjusted for study participants’ CCI) for the
association between partner bereavement and psoriasis was
101 (95% CI 098–104) (Fig. 2). Similar HRs in fully
adjusted models were observed (Table 3). We observed no
evidence of higher HRs (with 95% CIs) for psoriasis within
0–30 days (096, 068–135), 0–90 days (107, 088–129),
0–365 days (102, 091–114) or 0–1095 days (102, 097–
107) after bereavement (Fig. 2).
Atopic eczema
The pooled HR (adjusted for study participants’ CCI) for the
association between partner bereavement and atopic eczema
was 097 (95% CI 084–112) (Fig. 2). Estimates from fully
adjusted models were similar (Table 3). We did not find any
evidence of a higher HR for atopic eczema within 0–30 days
(109, 95% CI 086–138). However, we found evidence for
higher HRs for atopic eczema following partner bereavement
within 0–90 days and 0–365 days (HR 118, 95% CI 104–
135 and HR 114, 95% CI 106–122, respectively), and
some evidence within 0–1095 days (HR 107, 95% CI 102–
112) (Fig. 2).
Subgroup analyses
Figure 3 and Tables S3–6 (see Supporting Information) show
the results of subgroup analyses by age, sex and risk of part-
ners’ deaths for the entire follow-up and for 90 days. We
found evidence to suggest that HRs for psoriasis differed by
Fig 1. Flowchart for inclusion in the U.K. and Denmark cohorts.
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age (with a greater HR among the youngest) and partner
death following terminal disease in the U.K. We observed a
greater hazard of atopic eczema among those whose partners
had terminal disease in the U.K. The HR for atopic eczema
also differed by sex, with a greater hazard of atopic eczema
among men during the entire follow-up, and among women
during shorter follow-up of 90 days (U.K. only). No substan-
tial differences were observed for either psoriasis or atopic
eczema by characteristics (age, sex or risk of partner’s death)
in Denmark. Meaningful comparisons were hampered by low
power leading to wide CIs during 90-day follow-up in both
settings.
Additional and sensitivity analyses
In the U.K., missingness of lifestyle data was dependent on each
outcome, conditional on bereavement status and other covari-
ates (Table S7; see Supporting Information). However, HRs for
Table 1 Characteristics of the bereaved cohort and the matched comparison cohort, U.K. 1997–2017
Psoriasis Atopic eczema
Bereaved cohort Comparison cohorta Bereaved cohort Comparison cohortb
Total 163 884 (99) 1 488 293 (901) 145 065 (110) 1 178 404 (890)
Age at index date (years)
Range 319–1014 314–1004 319–1014 314–1004
Median (IQR) 746 (668–808) 738 (663–799) 743 (666–806) 734 (658–795)
< 50 2994 (18) 28 437 (19) 2731 (19) 23 831 (20)
50–59 15 301 (93) 148 055 (100) 14 011 (97) 124 042 (105)
60–69 37 667 (230) 361 687 (243) 34 109 (235) 296 968 (252)
70–79 61 614 (376) 585 139 (393) 54 631 (377) 462 374 (392)
≥ 80 46 308 (283) 364 975 (245) 39 583 (273) 271 189 (230)
Sex
Female 107 475 (656) 977 819 (657) 94 891 (654) 770 534 (654)
Male 56 409 (344) 510 474 (343) 50 174 (346) 407 870 (346)
Comorbidity burdenc
Low 71 961 (439) 684 789 (460) 65 411 (451) 561 217 (476)
Intermediate 60 087 (367) 534 239 (359) 52 652 (363) 417 890 (355)
High 31 836 (194) 269 265 (181) 27 002 (186) 199 297 (169)
Smoking status
Nonsmoker 59 789 (365) 589 185 (396) 53 122 (366) 471 023 (400)
Ex-smoker 66 186 (404) 614 171 (413) 57 296 (395) 471 448 (400)
Current smoker 35 216 (215) 264 591 (178) 32 096 (221) 218 062 (185)
Missing 2693 (16) 20 346 (14) 2551 (176) 17 871 (15)
Alcohol consumption
Nondrinker 19 259 (118) 158 969 (107) 17 159 (118) 127 203 (108)
Ex-drinker 21 173 (129) 171 885 (116) 18 461 (127) 133 949 (114)
Current drinker 110 602 (675) 1 054 171 (708) 97 492 (672) 830 080 (704)
Missing 12 850 (78) 103 268 (69) 11 953 (82) 87 172 (74)
Body mass index (kg m2)
< 185 4097 (25) 26 489 (18) 3528 (24) 20 460 (17)
185–249 55 915 (341) 508 746 (342) 49 100 (339) 397 340 (337)
25–299 56 763 (346) 548 587 (369) 50 242 (346) 434 394 (369)
≥ 30 34 255 (209) 307 143 (206) 30 338 (209) 244 068 (207)
Missing 12 854 (78) 97 328 (65) 11 857 (82) 82 142 (70)
Index of Multiple Deprivation
1 (least deprived) 38 286 (234) 372 476 (250) 33 358 (230) 286 681 (243)
2 34 097 (208) 322 582 (217) 30 008 (207) 252 586 (214)
3 35 357 (216) 321 404 (216) 31 641 (218) 258 947 (220)
4 31 904 (195) 273 268 (184) 28 621 (197) 223 338 (190)
5 (most deprived) 24 240 (148) 198 563 (133) 21 437 (148) 156 852 (133)
Follow-up (years)
Total 869 475 7 559 995 764 045 6 032 538
Median (IQR) 43 (18–80) 41 (18–75) 43 (17–80) 42 (18–76)
The data are presented as n (%) unless stated otherwise. Information on educational level was not available in the U.K. IQR, interquartile
range. aIn the U.K. comparison cohort, 188% (153% of unique individuals) experienced bereavement after the end of their follow-up. bIn
the U.K. comparison cohort, 190% (156% of unique individuals) experienced bereavement after the end of their follow-up. cComorbidity
burden was measured by the Charlson Comorbidity Index score defined at the index date and categorized as low (0 point), intermediate (1–
2 points) or high (≥ 3 points).
© 2019 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd
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the whole cohort and complete-case cohort were similar in
unadjusted and adjusted models in both settings (Table S8; see
Supporting Information). We investigated changes in HRs dur-
ing several stratified follow-up periods (Table S9; see Support-
ing Information) and observed differences in HRs for atopic
eczema in the U.K., with the highest HR during 31–90 days of
follow-up (HR 123, 95% CI 105–144).
In a sensitivity analysis in which the matched cohort was
redefined (without replacement) in the U.K., the adjusted HR
for atopic eczema was of lower magnitude during 0–90 days
than in the main analysis (HR 106, 95% CI 086–129)
(Table S10; see Supporting Information). All other sensitivity
analyses yielded findings similar to those of the main analysis
(Tables S11–18; see Supporting Information).
Discussion
In this large matched-cohort study, we found increased risk of
atopic eczema up to 3 years following partner bereavement. It
peaked during the first 3 months, supporting the role of acute
stress in triggering onset or relapse of atopic eczema episodes
in the short term. However, we observed no evidence for
overall long-term increased risk of psoriasis or atopic eczema
following partner bereavement.
The death of a partner is extremely stressful, yet coping
mechanisms and life circumstances might vary between indi-
viduals. While we could not measure the level and duration of
stress arising from bereavement, we examined associations in
certain subgroups as proxies. It is possible that young partners
find partner bereavement more stressful or more unexpected
than older individuals; we observed an increased risk of psori-
asis among bereaved persons aged < 50 years in the U.K.
Specific types of stress, such as the partner’s disease process
leading up to death, may also be of importance.
While there was no evidence that low risk of partner death
(as a proxy for unexpected death) was associated with more
pronounced risk in our study, those whose partners had a ter-
minal disease had increased risk of both psoriasis and atopic
eczema in the U.K. This may reflect the effect of chronic stress
experienced while providing long-term care for a terminally
ill partner. Notably, this could not be confirmed in our study
as we did not have information on whether they took care of
Table 2 Characteristics of the bereaved cohort and the matched comparison cohort, Denmark 1997–2016
Psoriasis Atopic eczema
Bereaved cohort Comparison cohorta Bereaved cohort Comparison cohortb
Total 358 436 (95) 3 403 984 (905) 364 483 (94) 3 518 529 (906)
Age at index date (years)
Range 165–1003 161–1007 165–1003 161–1007
Median (IQR) 714 (626–789) 709 (622–782) 714 (626–789) 710 (623–782)
< 50c 24 495 (68) 241 834 (71) 24 692 (68) 245 478 (70)
50–59 46 176 (129) 454 364 (133) 46 874 (129) 467 861 (133)
60–69 91 802 (256) 900 974 (265) 93 531 (257) 934 857 (266)
70–79 119 295 (333) 1 156 594 (340) 121 520 (333) 1 198 904 (341)
≥ 80 76 668 (214) 650 218 (191) 77 866 (214) 671 429 (191)
Sex
Female 239 227 (667) 2 269 590 (667) 243 250 (667) 2 345 321 (667)
Male 119 209 (333) 1 134 394 (333) 121 233 (333) 1 173 208 (333)
Comorbidity burdend
Low 254 543 (710) 2 485 139 (730) 258 225 (708) 2 561 298 (728)
Intermediate 86 334 (241) 768 017 (226) 88 208 (242) 798 899 (227)
High 17 559 (49) 150 828 (44) 18 050 (50) 158 332 (45)
Educational level
Short 162 465 (453) 1 396 665 (410) 165 112 (453) 1 442 105 (410)
Medium 108 041 (301) 1 092 620 (321) 110 134 (302) 1 133 158 (322)
Long 42 943 (120) 548 745 (161) 43 779 (120) 569 309 (162)
Missing 44 987 (126) 365 954 (108) 45 458 (125) 373 957 (106)
Follow-up (years)
Total 2 737 250 23 357 938 2 791 720 24 138 608
Median (IQR) 67 (30–116) 57 (25–104) 68 (31–117) 57 (25–104)
The data are presented as n (%) unless stated otherwise. Information on smoking status, alcohol consumption, body mass index and Index of
Multiple Deprivation was not available in Denmark. aIn the Danish comparison cohort, 227% (170% of unique individuals) experienced
bereavement after the end of their follow-up. bIn the Danish comparison cohort, 214% (160% of unique individuals) experienced bereave-
ment after the end of their follow-up. cFor psoriasis, 7660 patients (21%) and 75 471 patients (22%) aged < 40 years were in the bereaved
and comparison cohorts, respectively. For atopic eczema, 7679 patients (21%) and 75 864 patients (22%) aged < 40 years were in the
bereaved and comparison cohorts, respectively. dComorbidity burden was measured by the Charlson Comorbidity Index score defined at the
index date and categorized as low (0 point), intermediate (1–2 points) or high (≥ 3 points).
© 2019 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd
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their partners, and if they did, what their stress level was
while taking care of their partners who had terminal illness.
Future research specifically investigating chronic stress is
required to test this hypothesis. The U.K. study also revealed
an overall increased risk of atopic eczema following partner
bereavement in men but not in women; this requires further
investigation.
While it is generally perceived that atopic eczema more
commonly develops in children, a recent study reported that
approximately 40% of individuals with atopic eczema had
onset of symptoms in adulthood.43 We may not have cap-
tured all historical records of psoriasis or atopic eczema.
However, we obtained similar findings when a longer prebe-
reavement follow-up period (3 years) was required. Our find-
ings were also consistent in a post hoc sensitivity analysis that
retained individuals with prevalent psoriasis or atopic eczema
in order to examine the effects of bereavement on disease
worsening. A short-term increased risk of atopic eczema
could reflect poorer management of existing disease in the
postbereavement phase. As this post hoc analysis was explora-
tory, it is important for future studies to investigate the role
of stress in flare-ups.
Similarly to our study, a nested case–control study using
CPRD data found no evidence of an increased risk of psoria-
sis associated with stress disorder diagnosed within the previ-
ous year (adjusted odds ratio 123, 95% CI 083–182),44
but the type of stress disorder was not specified. A system-
atic review21 that pooled results from five case–control
studies reported a threefold increase in risk of psoriasis onset
associated with preceding stressful events.44–48 Two addi-
tional case–control studies demonstrated an association
between stressful life events and psoriasis.49,50 However, sev-
eral different types of stress were measured in these studies,
including stress disorder and a combination of life events
related to family, personal illness, school, work or hormonal
changes. This might account for the large amount of hetero-
geneity found in the meta-analysis.
Unlike previous studies, we used partner bereavement as a
proxy for stress, to minimize heterogeneity in exposure to dif-
ferent types of stress. A Swedish cohort study that used match-
ing and sibling analyses found an increased risk of various
autoimmune disorders, including psoriasis, associated with
stress-related disorder.51 Stress-related disorders and partner
bereavement reflect different types of stress, in which the for-
mer is more long term and the latter is relatively short term.
The Swedish study might lend support to the role of chronic
stress in immune-mediated skin disorders. Future studies are
warranted to elucidate the association between chronic stress
and onset or worsening of skin disorders.
Regarding atopic eczema, our findings are consistent with a
cohort study that examined the association between perceived
stress and self-reported atopic eczema.52 A seven-point stress
score based on assessment of both intensity and frequency of
stress was used to measure stress level. A dose–response effect
of stress on atopic eczema was found, but the investigators
did not indicate how the level of stress was categorized as
Fig 2. Pooled adjusted hazard ratios with confidence intervals (CIs) from the meta-analysis in the U.K. and Denmark. Hazard ratios were adjusted
by Charlson Comorbidity Index score.
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low, medium or high based on the stress scores. Also, as data
were lacking on atopic eczema at baseline, individuals with a
history of atopic eczema were not excluded.
Our study is the first population-based study to investigate
the association between partner bereavement and psoriasis and
atopic eczema. Strengths include a large sample size and use
of population-based data in settings with universal healthcare.
Recording of deaths in the healthcare databases is of high
quality; hence, partner bereavement was a reliable exposure
with quite specific onset compared with other stressful life
events. In addition, both psoriasis and atopic eczema are vali-
dated outcomes for epidemiological studies.36–38 Importantly,
we used data from different settings in the U.K. and Denmark
to confirm our findings.
Table 3 Results of the main analysis for the associations between partner bereavement and skin disorders in different time intervals, for U.K.
(1997–2017) and Denmark (1997–2016)
Time since
index
date
Bereaved cohort Matched comparators
Unadjusted HR
(95% CI)a
Adjusted HR
(95% CI)b
Fully adjusted
HR (95% CI)c
Number
of events
Person-
years
at risk
Rate
per
1000
Number
of events
Person-years
at risk
Rate per
1000
U.K.
Psoriasis
Entire
follow-up
1524 869 475 175 13 789 7 559 996 182 099 (093–104) 099 (093–104) 097 (092–103)
0–30 days 26 13 357 195 240 121 532 197 098 (065–147) 098 (065–148) 094 (061–147)
0–90 days 88 39 431 223 705 359 967 196 115 (092–144) 115 (092–144) 114 (091–145)
0–365 days 299 150 129 199 2562 1 376 306 186 108 (096–122) 108 (096–122) 105 (093–120)
0–1095 days 741 387 992 191 6547 3 535 938 185 104 (097–113) 104 (096–112) 104 (096–113)
Atopic eczema
Entire
follow-up
5034 764 045 659 38 130 6 032 538 632 102 (099–105) 102 (099–105) 101 (098–104)
0–30 days 79 11 821 668 566 96 225 588 110 (087–140) 110 (087–139) 104 (080–134)
0–90 days 257 34 886 737 1734 285 081 608 119 (104–135) 118 (103–134) 116 (100–133)
0–365 days 959 132 689 723 6788 1 090 887 622 114 (107–122) 114 (106–122) 113 (105–121)
0–1095 days 2378 342 296 695 17 805 2 808 190 634 107 (103–112) 107 (102–112) 106 (101–111)
Denmark
Psoriasis
Entire
follow-up
3339 2 737 250 122 28 724 23 357 938 123 102 (098–106) 102 (098–106) 102 (098–106)
0–30 days 11 29 300 038 115 278 260 041 090 (049–168) 090 (048–168) 082 (041–162)
0–90 days 47 87 183 054 475 827 167 057 096 (071–130) 094 (069–127) 092 (067–127)
0–365 days 301 341 647 088 2945 3 220 429 091 097 (086–109) 096 (086–109) 095 (084–108)
0–1095 days 1011 936 657 108 9416 8 655 697 109 100 (094–107) 100 (094–107) 101 (094–108)
Atopic eczema
Entire
follow-up
132 2 791 720 005 1325 24 138 689 005 088 (073–106) 087 (072–105) 089 (073–107)
0–30 days d 29 795 d d 287 620 d 050 (007–373) 054 (007–405) 058 (008–441)
0–90 days 6 88 650 007 48 854 945 006 124 (053–289) 126 (054–295) 151 (063–363)
0–365 days 20 347 403 006 186 3 328 093 006 106 (067–168) 103 (065–165) 105 (065–171)
0–1095 days 46 952 824 005 478 8 944 428 005 093 (069–126) 092 (068–125) 094 (068–128)
HR, hazard ratio; CI, confidence interval. aComputed using Cox regression stratified by matched set to account for matching variables of age,
sex, county of residence (in Denmark) and general practice (in the U.K.). bAdjusted for Charlson Comorbidity Index. cComplete-case analysis
was used to handle missing data in the fully adjusted model. Notably, the number of events, person-years at risk and rate per 1000 in the
bereaved and matched comparators cohorts presented in this table were calculated in the full cohort for the unadjusted and adjusted models
only. The data were adjusted additionally for smoking status, body mass index, alcohol consumption and socioeconomic status in the U.K.
For psoriasis, the total numbers of bereaved and comparison individuals were 144 873 and 1 211 218, respectively, after excluding patients
with missing values of body mass index, alcohol consumption and smoking status. For atopic eczema, the total numbers of bereaved and
comparison individuals were 127 477 and 946 178, respectively, after excluding patients with missing values of body mass index, alcohol
consumption and smoking status. The data were adjusted additionally for education level in Denmark. For psoriasis, the total numbers of
bereaved and comparison individuals were 312 875 and 2 938 214, respectively, after excluding patients with missing education level. For
atopic eczema, the total numbers of bereaved and comparison individuals were 318 445 and 3 041 376, respectively, after excluding patients
with missing education level. dWhere there were fewer than five patients the exact number has been withheld in accordance with the confi-
dentiality rules of the Clinical Practice Research Datalink and Danish registries.
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Although we were able to adjust for potential confounders,
including deprivation status and lifestyle variables, residual
confounding remains possible. Another concern is that we
matched our cohort with replacement in the main analysis in
both settings, which might have led to overconfidence in our
estimates. Partnership status may have been misclassified, par-
ticularly in the U.K. where direct data on relationship status
was unavailable. To minimize such misclassification we used
relatively strict criteria for partner identification (e.g. accept-
able age differences between partners), which has been suc-
cessful in other contexts.26,27,29,30 Detailed data on
partnership, including the change in partnership status, were
available in Denmark, which complement U.K. findings.
In the Danish study, skin disease outcomes were recorded
in a hospital setting, resulting in a potential delay between
actual disease onset and diagnosis in our study. Furthermore,
they are more likely to represent severe cases. In contrast,
mild-to-moderate cases diagnosed in primary care were
included in the U.K. study. Moreover, as the data were cap-
tured since birth in the Danish setting, medical history of pso-
riasis or atopic eczema in a hospital setting during childhood
might be more completely recorded compared with the U.K.
Finally, partner bereavement may affect disease perception,
health-seeking behaviour or heightened diagnostic efforts, and
thus ascertainment of outcomes. Such bias may have led to
short-term change in outcome detection and over-representa-
tion of the most severe skin diseases.
In conclusion, in this study we observed a modest increase
in risk of atopic eczema within 3 years of partner bereave-
ment, which peaked during the first 3 months (18% increase
in risk). Underlying mechanisms may include the impact of
acute stress on the immune system or on management of
existing atopic eczema conditions immediately following
bereavement.
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